A L Wong1, R A Soo1, D S Tan2, S C Lee1, J S Lim3, P C Marban4, L R Kong5, Y J Lee5, L Z Wang6, W L Thuya5, R Soong5, M Q Yee5, T M Chin1, M T Cordero4, B R Asuncion5, B Pang5, S Pervaiz7, J L Hirpara5, A Sinha8, W W Xu9, M Yuasa10, T Tsunoda10, M Motoyama10, T Yamauchi11, B C Goh12. 1. Department of Haematology-Oncology, National University Health System; Haematology Oncology Research Group, National University Cancer Institute of Singapore, National University Health System; Cancer Science Institute. 2. Department of Medical Oncology, National Cancer Centre. 3. Department of Haematology-Oncology, National University Health System; Haematology Oncology Research Group, National University Cancer Institute of Singapore, National University Health System. 4. Haematology Oncology Research Group, National University Cancer Institute of Singapore, National University Health System. 5. Cancer Science Institute. 6. Cancer Science Institute; Departments of Pharmacology. 7. Physiology, Yong Loo Lin School of Medicine. 8. Department of Diagnostic Imaging, National University Health System, Singapore. 9. Otsuka Beijing Research Institute, Beijing, China. 10. Otsuka Pharmaceutical Co., Ltd, Chiyoda-ku. 11. Fuji Memorial Research Institute, Otsuka Pharmaceutical Co. Ltd, Chiyoda-ku, Japan. 12. Department of Haematology-Oncology, National University Health System; Haematology Oncology Research Group, National University Cancer Institute of Singapore, National University Health System; Cancer Science Institute; Departments of Pharmacology. Electronic address: phcgbc@nus.edu.sg.
Abstract
BACKGROUND: The aim of this study was to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor, in patients with refractory solid tumors. PATIENTS AND METHODS: Three cohorts were studied: cohort A, a sequential dose escalation of OPB-51602 administered intermittently (days 1-14 every 21 days); cohort B, an expansion cohort evaluating the dose lower than the MTD; cohort C, evaluating continuous daily dosing. RESULTS: Fifty-one patients were studied at 2, 4, and 5 mg per day dosing. The MTD was 5 mg; first-cycle dose-limiting toxicities (DLTs) were grade 3 hyponatremia in one patient, and grade 3 dehydration in another. Intermittent dosing of both 2 and 4 mg doses were tolerable, and the recommended phase II dose was 4 mg. Cohort B investigated 4 mg intermittently, whereas cohort C investigated 4 mg continuously. Common toxicities included fatigue, nausea/vomiting, diarrhea, anorexia, and early-onset peripheral neuropathy. Drug-induced pneumonitis occurred in two patients in cohort C. Continuous dosing was associated with a higher incidence of peripheral neuropathy and a lower mean relative dose intensity, compared with intermittent dosing. Steady-state pharmacokinetics was characterized by high oral clearance, mean elimination half-life ranging from 44 to 61 h, and a large terminal-phase volume of distribution. An active metabolite, OPB-51822, accumulated to a greater extent than OPB-51602. Flow cytometry of peripheral blood mononuclear cells demonstrated pSTAT3 (Tyr(705)) inhibition following exposure. Two patients achieved partial responses at 5 mg intermittently and 4 mg continuously; both had epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor exposure. CONCLUSION: OPB-51602 demonstrates promising antitumor activity, particularly in NSCLC. Its long half-life and poorer tolerability of continuous dosing, compared with intermittent dosing, suggest that less frequent dosing should be explored. CLINICALTRIALSGOV IDENTIFIER: NCT01184807.
BACKGROUND: The aim of this study was to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor, in patients with refractory solid tumors. PATIENTS AND METHODS: Three cohorts were studied: cohort A, a sequential dose escalation of OPB-51602 administered intermittently (days 1-14 every 21 days); cohort B, an expansion cohort evaluating the dose lower than the MTD; cohort C, evaluating continuous daily dosing. RESULTS: Fifty-one patients were studied at 2, 4, and 5 mg per day dosing. The MTD was 5 mg; first-cycle dose-limiting toxicities (DLTs) were grade 3 hyponatremia in one patient, and grade 3 dehydration in another. Intermittent dosing of both 2 and 4 mg doses were tolerable, and the recommended phase II dose was 4 mg. Cohort B investigated 4 mg intermittently, whereas cohort C investigated 4 mg continuously. Common toxicities included fatigue, nausea/vomiting, diarrhea, anorexia, and early-onset peripheral neuropathy. Drug-induced pneumonitis occurred in two patients in cohort C. Continuous dosing was associated with a higher incidence of peripheral neuropathy and a lower mean relative dose intensity, compared with intermittent dosing. Steady-state pharmacokinetics was characterized by high oral clearance, mean elimination half-life ranging from 44 to 61 h, and a large terminal-phase volume of distribution. An active metabolite, OPB-51822, accumulated to a greater extent than OPB-51602. Flow cytometry of peripheral blood mononuclear cells demonstrated pSTAT3 (Tyr(705)) inhibition following exposure. Two patients achieved partial responses at 5 mg intermittently and 4 mg continuously; both had epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor exposure. CONCLUSION: OPB-51602 demonstrates promising antitumor activity, particularly in NSCLC. Its long half-life and poorer tolerability of continuous dosing, compared with intermittent dosing, suggest that less frequent dosing should be explored. CLINICALTRIALSGOV IDENTIFIER: NCT01184807.
Authors: Kwang Hwa Jung; Wonbeak Yoo; Heather L Stevenson; Dipti Deshpande; Hong Shen; Mihai Gagea; Suk-Young Yoo; Jing Wang; T Kris Eckols; Uddalak Bharadwaj; David J Tweardy; Laura Beretta Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531
Authors: Emily A Irey; Chelsea M Lassiter; Nicholas J Brady; Pavlina Chuntova; Ying Wang; Todd P Knutson; Christine Henzler; Thomas S Chaffee; Rachel I Vogel; Andrew C Nelson; Michael A Farrar; Kathryn L Schwertfeger Journal: Proc Natl Acad Sci U S A Date: 2019-05-30 Impact factor: 11.205
Authors: Susan R Mallery; Daren Wang; Brian Santiago; Ping Pei; Steven P Schwendeman; Kari Nieto; Richard Spinney; Meng Tong; George Koutras; Brian Han; Andrew Holpuch; James Lang Journal: Cancer Prev Res (Phila) Date: 2016-10-18